Assistant Professor, Sociomedical Sciences, Columbia University Mailman School of Public Health
The Social Side Effects of Biomedical HIV Technologies: Facilitating the Roll-Out of Long-Acting Injectable ART and PrEP
April 28, 2021, 11:00 a.m. ET
Assistant Professor of Medicine, Beth Israel Deaconess Medical Center
Harvard Medical School
Dietary Patterns To Prevent Cardiovascular Disease
May 5, 2021, 11:00 a.m. ET
About Dr. Philbin
Morgan Philbin, Ph.D., M.H.S, is an Assistant Professor in the Department of Sociomedical Sciences at the Columbia University Mailman School of Public Health. Her mixed methods research explores how socio-structural factors can drive, and be used to prevent, HIV and substance use among marginalized young people, particularly sexual and gender minority youth. In addition, Dr. Philbin’s work examines the potential ‘social side effects’ and unintended consequences of substance use and HIV-related policies and practices, and their impact on young people. Dr. Philbin has conducted research on how these policies and practices influence adolescent and young adults’ HIV prevention, testing, and care engagement behaviors–her recent mixed-methods work has explored barriers and facilitators to the scale up of long-acting injectable antiretroviral therapy (ART) and PrEP (pre-exposure prophylaxis). Supported by a National Institute on Drug Abuse (NIDA) K01 award, she is examining how state-level HIV and substance use policies can impact health behaviors among sexual minority youth and young adults. Dr. Philbin’s research has been funded by several NIH institutes, including NIDA, the National Institute on Minority Health and Health Disparities, National Institute of Allergy and Infectious Diseases, and National Institute of Mental Health.
During her lecture, Dr. Philbin will discuss current research on long-acting injectable antiretroviral therapy (ART) and HIV pre-exposure prophylaxis (PrEP) with a focus on the multilevel barriers and facilitators to successful implementation. She will also highlight key points that must be addressed to scale up biomedical HIV technologies in ways that maximize population health impact and reduce existing disparities related to current formulations of PrEP and ART.
About Dr. Juraschek
Stephen Juraschek, M.D., Ph.D., is a physician investigator at Beth Israel Deaconess Medical Center and an Assistant Professor at Harvard Medical School. He has published over 100 papers (over half first-authored) from over 15 distinct cohorts. In addition, he participated in the primary publication of seven distinct clinical trials focused on nutrition and lifestyle interventions to improve clinical outcomes. He is currently the principal investigator on three NIH grants and is an internationally-recognized expert in blood pressure. Dr. Juraschek is passionate about the role of a healthy diet to lower blood pressure and prevent cardiovascular disease, which represents a major focus of his current work.
During his lecture, Dr. Juraschek will describe novel evidence in support of healthy dietary patterns to prevent mechanisms of subclinical cardiovascular damage. He will also discuss the status of healthy eating and opportunities to enhance adoption of healthy eating in the United States.